| IVACAFTOR; LUMACAFTOR | Vertex pharma | ||
| 125MG;200MG, 125MG;100MG ; Tablet |
Less Than $1000 mn
|
||
| None | None | ||
|
Less Than 5
|
None | ||
| None | None | ||
| ORKAMBI is a combination of lumacaftor and ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, indicated for the treatment of cystic fibrosis (CF) in patients age 2 years and older who are homozygous for the F508del mutation in the CFTR gene. If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene. | |||
|
Yes
| |||
| ORKAMBI | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 | Patent 18 | Patent 19 | Patent 20 | Patent 21 | Patent 22 | Patent 23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ********* | |||||||||||||||||||||||
| ********** ** ***-******* ******** ************ | ********** ** ***-******* ******** ************ | ********** ** ***-******* ******** ************ | ***** ***** ** *-[*,*-***(*,*-*************)-*-*************]-*,*-*******-*-************-*-*********** | ***** ***** ** *-[*,*-***(*,*-*************)-*-*************]-*,*-*******-*-************-*-*********** | ***** ***** ** *-[*,*-***(*,*-*************)-*-*************]-*,*-*******-*-************-*-*********** | ***** ***** ** *[*,*-***(*,*-*************)-*-*************]-*,*-*******-*-************-*-*********** | ********** ** ***-******* ******** ************ | ********** ** ***-******* ******** ************ | ************** ************ ** *-(*-(*-(*,*-*************[*][*,*]******-*-**) ***********************)-*-*************-*-**) ******* **** *** ************** ******* | ***** ***** ** *-(*-(*-(*,*-*************[*][*,*]******-*-**)***********************)-*-*************-*-**) ******* **** | ************** ************ ** *-(*-(*-(*,*-*************[*][*,*]******-*-**) ***********************)-*-*************-*-**) ******* **** *** ************** ******* | ***** ***** ** *-(*-(*-(*,*-*************[*][*,*]******-*-**)***********************)-*-*************-*-**) ******* **** | ***** ***** ** *-(*-(*-(*,*-*************[*][*,*]******-*-**) ***********************)-*-*************-*-**)******* **** | ***** ***** ** *-(*-(*-(*,*-*************[*][*,*]******-*-**)***********************)-*-*************-*-**) ******* **** | ***** ***** ** *-(*-(*-(*,*-*************[*][*,*]******-*-**) ***********************)-*-*************-*-**) ******* **** | ************** *********** *** *************** ******* | ************** *********** *** *************** ******* | ************** *********** *** *************** ******* | ****** ***** ** *-(*-(*-(*,*-*************[*] [*,*] ******-*-**) ***********************)-*-*************-*-**)******* **** | ***** ***** ** *-(*-(*-(*,*-*************[*][*,*]******-*-**) ***********************)-*-*************-*-**)******* **** | ****** ***** ** *-(*-(*-(*,*-*************[*] [*,*] ******-*-**) ***********************)-*-*************-*-**)******* **** | ********** ** ***-******* ******** ************ |
| IVACAFTOR; LUMACAFTOR | Vertex pharma | ||
| 125MG/PACKET;100MG/PACKET, 188MG/PACKET;150MG/PACKET, 94MG/PACKET;75MG/PACKET ; Granules |
Less Than $1000 mn
|
||
| None | None | ||
|
Less Than 5
|
None | ||
| None | None | ||
| ORKAMBI is a combination of lumacaftor and ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, indicated for the treatment of cystic fibrosis (CF) in patients age 2 years and older who are homozygous for the F508del mutation in the CFTR gene. If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene. | |||
|
Yes
| |||
| ORKAMBI | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 | Patent 18 | Patent 19 | Patent 20 | Patent 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ********* | |||||||||||||||||||||
| ********** ** ***-******* ******** ************ | ********** ** ***-******* ******** ************ | ********** ** ***-******* ******** ************ | ***** ***** ** *-[*,*-***(*,*-*************)-*-*************]-*,*-*******-*-************-*-*********** | ***** ***** ** *-[*,*-***(*,*-*************)-*-*************]-*,*-*******-*-************-*-*********** | ***** ***** ** *-[*,*-***(*,*-*************)-*-*************]-*,*-*******-*-************-*-*********** | ***** ***** ** *[*,*-***(*,*-*************)-*-*************]-*,*-*******-*-************-*-*********** | ********** ** ***-******* ******** ************ | ********** ** ***-******* ******** ************ | ***** ***** ** *-(*-(*-(*,*-*************[*][*,*]******-*-**)***********************)-*-*************-*-**) ******* **** | ***** ***** ** *-(*-(*-(*,*-*************[*][*,*]******-*-**)***********************)-*-*************-*-**) ******* **** | ***** ***** ** *-(*-(*-(*,*-*************[*][*,*]******-*-**) ***********************)-*-*************-*-**)******* **** | ***** ***** ** *-(*-(*-(*,*-*************[*][*,*]******-*-**)***********************)-*-*************-*-**) ******* **** | ***** ***** ** *-(*-(*-(*,*-*************[*][*,*]******-*-**) ***********************)-*-*************-*-**) ******* **** | ************** *********** *** *************** ******* | ************** *********** *** *************** ******* | ************** *********** *** *************** ******* | ****** ***** ** *-(*-(*-(*,*-*************[*] [*,*] ******-*-**) ***********************)-*-*************-*-**)******* **** | ***** ***** ** *-(*-(*-(*,*-*************[*][*,*]******-*-**) ***********************)-*-*************-*-**)******* **** | ****** ***** ** *-(*-(*-(*,*-*************[*] [*,*] ******-*-**) ***********************)-*-*************-*-**)******* **** | ********** ** ***-******* ******** ************ |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|